BeyondSpring is trading at $1.34 (up 8.1%) in pre-market, extending a rebound driven by recent first-quarter 2026 financial results.
- The company's latest earnings report showed a narrower net loss and highlighted significant progress across its clinical pipeline.
- The stock's advance follows a 3.9% decline on July 20, 2026, and appears to be supported by a broadly firmer risk backdrop in the absence of new company-specific headlines.